Glow Blend is a three-compound research-supply formulation containing the copper-complexed tripeptide GHK-Cu as the dominant component by mass, alongside two minor components — the gastric pentadecapeptide BPC-157 and the thymosin β4 fragment TB-500 — pre-formulated at fixed ratios in a single lyophilised vial. Per-component loadings are listed in the Definition section below. The three engage non-overlapping mechanism niches across skin and tissue-repair research.
Definition
Glow Blend is a 70 mg combined-formulation lyophilised vial containing three research peptides at fixed per-vial loadings. The dominant component by mass is GHK-Cu at 50 mg (the copper-complexed glycyl-histidyl-lysine tripeptide); the two minor components are the synthetic gastric pentadecapeptide BPC-157 at 10 mg per vial and the thymosin β4 fragment TB-500 at 10 mg per vial. Each component is also available as a single-compound vial in the Ronin catalog; the blend format pairs them at convenient working concentrations for combined-research workflows in skin-and-tissue-repair research contexts.
The lyophilised powder carries a characteristic blue tint from the Cu(II) chromophore of the GHK-Cu component — the copper-2 ion bound at the histidine-imidazole chelation pocket of the GHK tripeptide absorbs visible light in the orange-red wavelength range and transmits the complementary blue. The BPC-157 and TB-500 components do not contribute to the colour. Loss of the blue tint during storage signals dissociation of the GHK-Cu Cu(II) complex specifically but does not directly indicate the status of the BPC-157 or TB-500 components, which require COA mass-spectrometric data for status confirmation.
How the combination is used in research workflows
The mechanistic rationale for the combination is non-overlapping pathway engagement across three distinct research literatures. GHK-Cu engages copper-dependent fibroblast and keratinocyte signalling and the broader skin-regeneration gene-expression programs. BPC-157 engages the VEGFR2-Akt-eNOS angiogenic cascade on vascular endothelial cells. TB-500 engages G-actin sequestration and integrin-linked kinase signalling in endothelial and cardiac cell models. The three pathways do not compete at the receptor or signalling-pathway level.
A standard 70 mg vial reconstituted with 2 mL of bacteriostatic water yields GHK-Cu at 25 mg/mL, BPC-157 at 5 mg/mL, and TB-500 at 5 mg/mL simultaneously. Other diluent volumes scale linearly. The three peptides share the same diluent volume but contribute distinct working concentrations corresponding to their per-vial loadings (50 mg, 10 mg, 10 mg respectively). Researchers should choose the reconstitution volume based on which component’s working concentration is the primary experimental anchor.
Related terms
Where Glow Blend appears in the Ronin catalog
- Glow Blend 70mg — three-compound combined-formulation vial
- GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg — single-component standalone vials
- KLOW Blend — four-compound extension adding KPV to the same three components
References
Glossary entries describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Glow Blend is sold strictly as a research-grade reagent for laboratory and bench research applications.